Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 5/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 2/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.30 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.30 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.30 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.30 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.30 |
| ▸ | KDR | P35968 | 2/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035451 | 0.82 | CACNA2D1 (0.34) | AXLCHRNB2CHRNA4CACNA2D1PRKCZ | |
| SCHEMBL15041570 | 0.80 | CDK4 (0.48) | CCNA2CDK2CCNA1FGFR1FGFR2 | |
| SCHEMBL15035550 | 0.79 | CACNA2D1 (0.36) | AXLCACNA2D1 | |
| SCHEMBL15035506 | 0.72 | TYRO3 (0.36) | AXLCHEK1 | |
| SCHEMBL15035288 | 0.71 | NUAK1 (0.37) | AXLCCNA2CDK2CCNA1FGFR1 | |
| SCHEMBL15035271 | 0.67 | CDK4 (0.50) | CCNA2CDK2CCNA1EGFRFGFR1 | |
| SCHEMBL15035363 | 0.66 | CDK4 (0.41) | CCNA2CDK2EGFR | |
| SCHEMBL15041816 | 0.65 | CDK4 (0.47) | CCNA2CDK2CCNA1FGFR1FGFR2 | |
| SCHEMBL15035264 | 0.65 | CDK4 (0.51) | CCNA2CDK2CCNA1EGFRPDGFRB | |
| SCHEMBL15035399 | 0.64 | CAMK2D (0.39) | AXLCCNA2CDK2CCNA1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | AXL 1075/4885CHRNB2 4797/4885CHRNA4 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.